Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-catenin-accumulated crypts as a new biomarker.
Control of cell proliferation is important for cancer prevention since cell proliferation has essential roles in carcinogenesis in the processes of both initiation and promotion. In large bowel carcinogenesis, carcinogens produce hyperproliferation of cells in the target sites and the cell proliferation persists even after the cessation of carcinogen exposure. Chemopreventive agents principally control the increased cell proliferation when given in the initiation as well as post-initiation phases. Aberrant crypt foci (ACF) which appear soon after carcinogen exposure in large bowel carcinogenesis in rodents have been used as a reliable biomarker for screening of potential chemopreventive agents. Recently, our group demonstrated the presence of probable premalignant lesions with frequent beta-catenin gene mutations and accumulation of the corresponding protein in the colonic epithelium of rats given a large bowel carcinogen. Such early-appearing lesions lack the morphological appearance of ACF. Expression of these beta-catenin-accumulated crypts (BCAC) is markedly suppressed by a chemopreventive cyclooxygenase-2 inhibitor, celecoxib. BCAC are suggested to be more reliable biomarkers than ACF for screening effective chemopreventive agents for colorectal cancer and for investigating the mode of action of the agents.
Mori
H
H
Department of Pathology, Gifu University School of Medicine, 40 Tsukasa, Gifu 500-8705, Japan. hidmori@cc.gifu-u.ac.jp
Yamada
Y
Y
Hirose
Y
Y
Kuno
T
T
Katayama
M
M
Sakata
K
K
Yoshida
K
K
Sugie
S
S
Hara
A
A
Yoshimi
N
N
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis*; D002455:Cell Division / Q000187:drug effects*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000473:pathology; D018890:Chemoprevention / Q000379:methods*; D015179:Colorectal Neoplasms / Q000473:pathology / Q000517:prevention & control*; D003598:Cytoskeletal Proteins / Q000032:analysis*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007420:Intestine, Large / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051381:Rats; D012377:Rodentia; D012680:Sensitivity and Specificity; D015534:Trans-Activators / Q000032:analysis*; D051176:beta Catenin
D016588:Anticarcinogenic Agents; D015415:Biomarkers; C495270:CTNNB1 protein, human; C495268:Ctnnb1 protein, rat; D003598:Cytoskeletal Proteins; D015534:Trans-Activators; D051176:beta Catenin